Published in AIDS on November 04, 2005
Viral population estimation using pyrosequencing. PLoS Comput Biol (2008) 5.89
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis (2010) 2.45
Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One (2009) 1.91
Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol (2011) 1.44
Minority variants of drug-resistant HIV. J Infect Dis (2010) 1.44
Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods (2007) 1.43
Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options. J Infect Dis (2009) 1.20
Clinical implications of HIV-1 minority variants. Clin Infect Dis (2013) 1.09
MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J Clin Microbiol (2006) 1.01
Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure. PLoS One (2014) 0.99
Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One (2011) 0.98
Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay. J Clin Microbiol (2013) 0.98
Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One (2011) 0.93
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS (2010) 0.92
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission. PLoS One (2012) 0.90
Transmitted drug resistance in nonsubtype B HIV-1 infection. HIV Ther (2009) 0.90
Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLoS One (2014) 0.89
The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients. PLoS One (2013) 0.87
Hidden Empirical Research Ethics: A Review of Three Health Journals from 2005 through 2006. J Empir Res Hum Res Ethics (2008) 0.86
Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients. J Clin Microbiol (2007) 0.86
Primer ID Informs Next-Generation Sequencing Platforms and Reveals Preexisting Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Coding Domain. AIDS Res Hum Retroviruses (2015) 0.86
Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. Antimicrob Agents Chemother (2009) 0.86
Management of paediatric HIV-1 resistance. Curr Opin Infect Dis (2009) 0.81
The case for addressing primary resistance mutations to non-nucleoside reverse transcriptase inhibitors to treat children born from mothers living with HIV in sub-Saharan Africa. J Int AIDS Soc (2014) 0.81
Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China. PLoS One (2014) 0.77
Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child. PLoS One (2009) 0.75
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. PLoS One (2016) 0.75
Short communication: Simultaneous substitutions of V38M and N43T-N44K in the gp41 heptad repeat 1 (HR1) disrupt HIV type 1 gPr160 endoproteolytic cleavage (*). AIDS Res Hum Retroviruses (2010) 0.75
No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men. J Virol (2017) 0.75
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci U S A (2002) 3.46
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood (2009) 3.14
HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 2.72
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS (2002) 2.40
Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res (2003) 2.37
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis (2009) 2.36
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis (2009) 2.20
Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis (2009) 2.03
HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol (2010) 1.90
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther (2011) 1.90
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS (2002) 1.67
Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol (2003) 1.66
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis (2011) 1.64
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis (2015) 1.61
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis (2006) 1.42
The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer (2004) 1.39
Technologies for measuring HIV-1 drug resistance. HIV Clin Trials (2002) 1.39
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis (2010) 1.39
European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev (2011) 1.38
External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis (2011) 1.34
Transmission and long-term stability of compensated CD8 escape mutations. J Virol (2008) 1.29
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS (2012) 1.29
Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One (2010) 1.29
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS (2013) 1.29
Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease. J Virol (2007) 1.28
Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics (2005) 1.27
Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis (2010) 1.26
Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients. J Clin Virol (2010) 1.23
Understanding recent increases in the incidence of sexually transmitted infections in men having sex with men: changes in risk behavior from risk avoidance to risk reduction. Sex Transm Dis (2006) 1.20
A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS (2009) 1.18
Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. J Acquir Immune Defic Syndr (2008) 1.15
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS (2011) 1.13
Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol (2003) 1.11
Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care (2014) 1.10
CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. PLoS One (2008) 1.10
Tenofovir resistance and resensitization. Antimicrob Agents Chemother (2003) 1.10
Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther (2006) 1.09
Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS (2007) 1.07
Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. J Electrocardiol (2010) 1.06
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother (2004) 1.05
Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. Clin Infect Dis (2011) 1.05
Methods for optimizing antiviral combination therapies. Bioinformatics (2003) 1.02
Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. J Infect (2005) 1.02
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther (2013) 1.01
Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. J Immunol (2006) 1.01
Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort. PLoS One (2011) 1.00
Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol (2011) 0.99
HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology (2012) 0.97
Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine (2013) 0.96
Genotyping of hepatitis C virus types 1, 2, 3, and 4 by a one-step LightCycler method using three different pairs of hybridization probes. J Clin Microbiol (2002) 0.95
Multiple infections with different HCV genotypes: prevalence and clinical impact. J Clin Virol (2003) 0.95
Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS (2003) 0.95
Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J Clin Virol (2002) 0.95
Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol (2002) 0.94
Impaired CD4⁺ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J Hepatol (2013) 0.94
Antiviral activity of Arthrospira-derived spirulan-like substances. Antiviral Res (2006) 0.94
Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis (2011) 0.94
Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity. J Virol (2012) 0.93
Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS (2005) 0.92
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology (2007) 0.92
Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy. AIDS Rev (2002) 0.91
Mycotic brain abscess caused by opportunistic reptile pathogen. Emerg Infect Dis (2005) 0.91
Loss of HIV-1-specific T-cell responses associated with very rapid HIV-1 disease progression. AIDS (2007) 0.90
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS (2007) 0.90
Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. AIDS Patient Care STDS (2014) 0.90
Highly conserved serine residue 40 in HIV-1 p6 regulates capsid processing and virus core assembly. Retrovirology (2011) 0.90
Acute hepatitis C infection in HIV-positive patients. Curr Opin Infect Dis (2011) 0.89
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? AIDS Res Ther (2011) 0.88
Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccin (2011) 0.88
Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study. Eur J Health Econ (2012) 0.87
Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene (2002) 0.87
Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 0.86
Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy. J Infect Dis (2011) 0.86
Inhibition of drug-resistant HIV-1 by RNA interference. Antiviral Res (2005) 0.86
Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. AIDS (2013) 0.86
Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32. AIDS (2015) 0.85